NASDAQ:BSGM

BioSig Technologies Competitors

$3.43
-0.13 (-3.65 %)
(As of 04/20/2021 05:16 PM ET)
Add
Compare
Today's Range
$3.35
Now: $3.43
$3.72
50-Day Range
$3.88
MA: $4.42
$5.09
52-Week Range
$2.79
Now: $3.43
$12.43
Volume277,488 shs
Average Volume319,778 shs
Market Capitalization$109.04 million
P/E RatioN/A
Dividend YieldN/A
Beta1.83

Competitors

BioSig Technologies (NASDAQ:BSGM) Vs. EDAP, EYES, FONR, IRIX, NDRA, and SLNO

Should you be buying BSGM stock or one of its competitors? Companies in the industry of "electromedical equipment" are considered alternatives and competitors to BioSig Technologies, including Edap Tms (EDAP), Second Sight Medical Products (EYES), FONAR (FONR), IRIDEX (IRIX), ENDRA Life Sciences (NDRA), and Soleno Therapeutics (SLNO).

Edap Tms (NASDAQ:EDAP) and BioSig Technologies (NASDAQ:BSGM) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, dividends, institutional ownership, risk, profitability, analyst recommendations and earnings.

Earnings and Valuation

This table compares Edap Tms and BioSig Technologies' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Edap Tms$50.23 million4.84$1.69 million$0.06138.83
BioSig TechnologiesN/AN/A$-34,060,000.00N/AN/A

Edap Tms has higher revenue and earnings than BioSig Technologies.

Volatility and Risk

Edap Tms has a beta of 1.92, indicating that its share price is 92% more volatile than the S&P 500. Comparatively, BioSig Technologies has a beta of 1.83, indicating that its share price is 83% more volatile than the S&P 500.

Institutional & Insider Ownership

18.3% of BioSig Technologies shares are owned by institutional investors. 19.5% of BioSig Technologies shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Analyst Ratings

This is a summary of recent ratings and target prices for Edap Tms and BioSig Technologies, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Edap Tms00303.00
BioSig Technologies0000N/A

Edap Tms presently has a consensus price target of $12.50, suggesting a potential upside of 51.33%. Given Edap Tms' higher possible upside, research analysts plainly believe Edap Tms is more favorable than BioSig Technologies.

Profitability

This table compares Edap Tms and BioSig Technologies' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Edap Tms-4.03%-11.54%-5.78%
BioSig TechnologiesN/A-244.64%-213.88%

Summary

Edap Tms beats BioSig Technologies on 7 of the 10 factors compared between the two stocks.

BioSig Technologies (NASDAQ:BSGM) and Second Sight Medical Products (NASDAQ:EYES) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, analyst recommendations, institutional ownership, risk, dividends, earnings and profitability.

Volatility & Risk

BioSig Technologies has a beta of 1.83, indicating that its stock price is 83% more volatile than the S&P 500. Comparatively, Second Sight Medical Products has a beta of 2.49, indicating that its stock price is 149% more volatile than the S&P 500.

Profitability

This table compares BioSig Technologies and Second Sight Medical Products' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
BioSig TechnologiesN/A-244.64%-213.88%
Second Sight Medical ProductsN/A-977.63%-291.02%

Analyst Recommendations

This is a breakdown of current recommendations and price targets for BioSig Technologies and Second Sight Medical Products, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
BioSig Technologies0000N/A
Second Sight Medical Products0000N/A

Earnings and Valuation

This table compares BioSig Technologies and Second Sight Medical Products' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BioSig TechnologiesN/AN/A$-34,060,000.00N/AN/A
Second Sight Medical Products$3.38 million60.60$-33,590,000.00($1.91)-3.84

Second Sight Medical Products has higher revenue and earnings than BioSig Technologies.

Institutional & Insider Ownership

18.3% of BioSig Technologies shares are held by institutional investors. Comparatively, 4.1% of Second Sight Medical Products shares are held by institutional investors. 19.5% of BioSig Technologies shares are held by company insiders. Comparatively, 67.5% of Second Sight Medical Products shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Second Sight Medical Products beats BioSig Technologies on 4 of the 7 factors compared between the two stocks.

BioSig Technologies (NASDAQ:BSGM) and FONAR (NASDAQ:FONR) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, analyst recommendations, institutional ownership, valuation, dividends, earnings and profitability.

Profitability

This table compares BioSig Technologies and FONAR's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
BioSig TechnologiesN/A-244.64%-213.88%
FONAR8.28%5.57%3.99%

Valuation & Earnings

This table compares BioSig Technologies and FONAR's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BioSig TechnologiesN/AN/A$-34,060,000.00N/AN/A
FONAR$85.69 million1.35$8.24 millionN/AN/A

FONAR has higher revenue and earnings than BioSig Technologies.

Volatility and Risk

BioSig Technologies has a beta of 1.83, meaning that its stock price is 83% more volatile than the S&P 500. Comparatively, FONAR has a beta of 1.07, meaning that its stock price is 7% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent ratings for BioSig Technologies and FONAR, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
BioSig Technologies0000N/A
FONAR0000N/A

Institutional and Insider Ownership

18.3% of BioSig Technologies shares are held by institutional investors. Comparatively, 62.1% of FONAR shares are held by institutional investors. 19.5% of BioSig Technologies shares are held by insiders. Comparatively, 8.6% of FONAR shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

FONAR beats BioSig Technologies on 6 of the 8 factors compared between the two stocks.

BioSig Technologies (NASDAQ:BSGM) and IRIDEX (NASDAQ:IRIX) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, profitability, analyst recommendations, dividends, institutional ownership, valuation and risk.

Analyst Recommendations

This is a breakdown of recent recommendations for BioSig Technologies and IRIDEX, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
BioSig Technologies0000N/A
IRIDEX00203.00

IRIDEX has a consensus price target of $6.50, suggesting a potential downside of 8.19%. Given IRIDEX's higher possible upside, analysts clearly believe IRIDEX is more favorable than BioSig Technologies.

Volatility and Risk

BioSig Technologies has a beta of 1.83, meaning that its share price is 83% more volatile than the S&P 500. Comparatively, IRIDEX has a beta of 1.2, meaning that its share price is 20% more volatile than the S&P 500.

Institutional & Insider Ownership

18.3% of BioSig Technologies shares are owned by institutional investors. Comparatively, 32.6% of IRIDEX shares are owned by institutional investors. 19.5% of BioSig Technologies shares are owned by company insiders. Comparatively, 2.0% of IRIDEX shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Valuation & Earnings

This table compares BioSig Technologies and IRIDEX's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BioSig TechnologiesN/AN/A$-34,060,000.00N/AN/A
IRIDEX$43.45 million2.53$-8,810,000.00($0.64)-11.05

IRIDEX has higher revenue and earnings than BioSig Technologies.

Profitability

This table compares BioSig Technologies and IRIDEX's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
BioSig TechnologiesN/A-244.64%-213.88%
IRIDEX-21.54%-38.60%-24.99%

Summary

IRIDEX beats BioSig Technologies on 7 of the 10 factors compared between the two stocks.

ENDRA Life Sciences (NASDAQ:NDRA) and BioSig Technologies (NASDAQ:BSGM) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, valuation, earnings and profitability.

Earnings and Valuation

This table compares ENDRA Life Sciences and BioSig Technologies' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ENDRA Life Sciences$10,000.009,152.00$-13,310,000.00($2.34)-0.94
BioSig TechnologiesN/AN/A$-34,060,000.00N/AN/A

ENDRA Life Sciences has higher revenue and earnings than BioSig Technologies.

Insider and Institutional Ownership

2.8% of ENDRA Life Sciences shares are held by institutional investors. Comparatively, 18.3% of BioSig Technologies shares are held by institutional investors. 9.6% of ENDRA Life Sciences shares are held by company insiders. Comparatively, 19.5% of BioSig Technologies shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Risk and Volatility

ENDRA Life Sciences has a beta of 1.6, suggesting that its share price is 60% more volatile than the S&P 500. Comparatively, BioSig Technologies has a beta of 1.83, suggesting that its share price is 83% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for ENDRA Life Sciences and BioSig Technologies, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
ENDRA Life Sciences0000N/A
BioSig Technologies0000N/A

Profitability

This table compares ENDRA Life Sciences and BioSig Technologies' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
ENDRA Life SciencesN/A-492.76%-288.58%
BioSig TechnologiesN/A-244.64%-213.88%

Summary

BioSig Technologies beats ENDRA Life Sciences on 5 of the 7 factors compared between the two stocks.

BioSig Technologies (NASDAQ:BSGM) and Soleno Therapeutics (NASDAQ:SLNO) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, valuation, dividends, profitability, analyst recommendations, institutional ownership and risk.

Earnings and Valuation

This table compares BioSig Technologies and Soleno Therapeutics' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BioSig TechnologiesN/AN/A$-34,060,000.00N/AN/A
Soleno TherapeuticsN/AN/A$-30,770,000.00($0.70)-1.57

Risk & Volatility

BioSig Technologies has a beta of 1.83, suggesting that its stock price is 83% more volatile than the S&P 500. Comparatively, Soleno Therapeutics has a beta of 0.71, suggesting that its stock price is 29% less volatile than the S&P 500.

Profitability

This table compares BioSig Technologies and Soleno Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
BioSig TechnologiesN/A-244.64%-213.88%
Soleno TherapeuticsN/A-88.69%-51.63%

Analyst Recommendations

This is a breakdown of current ratings and price targets for BioSig Technologies and Soleno Therapeutics, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
BioSig Technologies0000N/A
Soleno Therapeutics00303.00

Soleno Therapeutics has a consensus target price of $8.6667, indicating a potential upside of 687.88%. Given Soleno Therapeutics' higher possible upside, analysts clearly believe Soleno Therapeutics is more favorable than BioSig Technologies.

Insider and Institutional Ownership

18.3% of BioSig Technologies shares are held by institutional investors. Comparatively, 55.4% of Soleno Therapeutics shares are held by institutional investors. 19.5% of BioSig Technologies shares are held by insiders. Comparatively, 74.9% of Soleno Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

Soleno Therapeutics beats BioSig Technologies on 7 of the 8 factors compared between the two stocks.


BioSig Technologies Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Edap Tms logo
EDAP
Edap Tms
1.3$8.33-2.2%$248.00 million$50.23 million-138.83Increase in Short Interest
Gap Down
Second Sight Medical Products logo
EYES
Second Sight Medical Products
0.8$7.34-4.9%$194.80 million$3.38 million-3.84Decrease in Short Interest
FONR
FONAR
1.1$17.62-1.6%$117.38 million$85.69 million16.62
IRIDEX logo
IRIX
IRIDEX
0.9$7.07-5.0%$115.17 million$43.45 million-12.85Gap Up
ENDRA Life Sciences logo
NDRA
ENDRA Life Sciences
0.6$2.20-4.1%$95.26 million$10,000.00-1.20Analyst Downgrade
Gap Up
Soleno Therapeutics logo
SLNO
Soleno Therapeutics
1.9$1.10-7.3%$94.07 millionN/A-1.45Analyst Downgrade
Increase in Short Interest
electroCore logo
ECOR
electroCore
1.4$1.74-6.3%$89.68 million$2.39 million-2.20Gap Down
Helius Medical Technologies logo
HSDT
Helius Medical Technologies
1.3$17.10-1.2%$39.98 million$1.50 million-0.98
CHF Solutions logo
CHFS
CHF Solutions
1.7$5.03-5.4%$32.00 million$5.51 million-0.10Increase in Short Interest
News Coverage
Viveve Medical logo
VIVE
Viveve Medical
0.9$2.63-2.7%$26.48 million$6.57 million-0.01
Star Equity logo
STRR
Star Equity
0.1$2.76-3.6%$13.09 million$114.18 million-0.88
This page was last updated on 4/20/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.